Biotech Beyond Borders Report finds that the biotech industry is grappling with a wave of challenges, including ongoing ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.’ The medical device maker gave ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

COPD study initiation expands SKB378/WIN378 development into a second major respiratory diseaseSKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...

GSK’s latest hepatology partnership is posing a less-asked question—how do you stop patients’ liver fibrosis from regressing?

Biotech firms develop drugs from living organisms; pharma from chemicals. Biotech products require a Biologics License Application for FDA approval. Investing focus should be on the long-term ...